Latest market price
3.65
+0.15+4.29%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.14 | Insider Own | 4.17% | Shs Outstand | 321.54M | Perf Week | 13.00% |
| Market Cap | 1.17B | Forward P/E | — | EPS next Y | 0.00 | Insider Trans | -1.55% | Shs Float | 306.97M | Perf Month | -3.95% |
| Enterprise Value | 1.39B | PEG | — | EPS next Q | -0.06 | Short Float | 8.30% | Perf Quarter | -7.83% | ||
| Income | -44.00M | P/S | 2.99 | EPS this Y | -210.89% | Short Ratio | 5.58 | Perf Half Y | 29.89% | ||
| Sales | 393.00M | P/B | — | EPS next Y | — | ROA | -5.96% | Short Interest | 25.48M | Perf YTD | -35.63% |
| Book/sh | -0.21 | P/C | 10.57 | EPS next 5Y | — | ROE | — | 52W High | 6.51 -43.93% | Perf Year | -34.23% |
| Cash/sh | 0.35 | P/FCF | — | EPS past 3/5Y | — | ROIC | 1.18% | 52W Low | 2.23 63.68% | Perf 3Y | -9.65% |
| Dividend Est. | — | EV/EBITDA | 47.99 | Sales past 3/5Y | 51.68% 39.95% | Gross Margin | 75.69% | Volatility | 4.56% 5.06% | Perf 5Y | -19.78% |
| Dividend TTM | — | EV/Sales | 3.54 | EPS Y/Y TTM | -225.73% | Oper. Margin | 1.97% | ATR (14) | 0.18 | Perf 10Y | 22.83% |
| Dividend Ex-Date | — | Quick Ratio | 1.41 | Sales Y/Y TTM | 30.13% | Profit Margin | -11.08% | RSI (14) | 60.99 | Recom | 2.81 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.72 | EPS Q/Q | — | SMA20 | 11.40% | Beta | 1.08 | Target Price | 10.00 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 41.56% | SMA50 | 2.16% | Rel Volume | 0.77 | Prev Close | 3.50 |
| Employees | 592 | LT Debt/Eq | — | Earnings | Nov 05 | SMA200 | -1.88% | Avg Volume | 4.14M | Price | 3.65 |
| IPO Date | Jul 28, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -700.00% 1.20% | Net Debt/EBITDA | 7.52 | Volume | 3,174,857 | Change | 4.29% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Initiated | Chardan | Buy | $10 |
| Aug-06-26 | Reiterated | Wells Fargo | Overweight | $14 → $13 |
| Jul-30-26 | Reiterated | Wells Fargo | Overweight | $11 → $14 |
| Jun-01-26 | Reiterated | Wells Fargo | Overweight | $10 → $11 |
| May-07-26 | Reiterated | Mizuho | Outperform | $8.00 → $7.00 |
| May-07-26 | Reiterated | Wells Fargo | Overweight | $10 |
| May-07-26 | Reiterated | HC Wainwright & Co. | Buy | $11 → $10 |
| Apr-13-26 | Reiterated | Mizuho | Outperform | $8.00 |
| Apr-08-26 | Reiterated | Truist Financial | $7.00 → $6.00 | |
| Feb-27-26 | Downgrade | RBC Capital | Outperform → Sector Perform |
Latest News· Times ET
Oct-29-26
Oct-29-2604:01PM
Oct-20-26
Oct-20-2604:03PM
Oct-19-26
Oct-19-2609:16AM
Oct-15-26
Oct-15-2608:21PM
Oct-14-26
Oct-09-26
Oct-09-2608:00PM
Oct-07-26
Sep-27-26
Sep-17-26
Sep-17-2606:02PM
Sep-15-26
Sep-09-26
Sep-09-2607:34AM
06:30AM
Sep-02-26
Aug-28-26
Company
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 393 | 349 | 286 | 199 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 96 | 61 | 77 | 63 | — | — | — | — | — | |
| Gross Profit | 298 | 288 | 209 | 136 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 199 | 144 | 94 | 94 | — | — | — | — | — | |
| Research and Development | 77 | 66 | 46 | 31 | — | — | — | — | — | |
| Other Operating Expense | 14 | 39 | -4 | 3 | — | — | — | — | — | |
| Operating Income | 8 | 39 | 73 | 9 | — | — | — | — | — | |
| Interest Expense | 44 | 14 | 38 | 25 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -12 | -24 | -4 | 6 | — | — | — | — | — | |
| Net Income Before Taxes | -48 | 1 | 31 | -10 | — | — | — | — | — | |
| Income Taxes | -5 | -4 | 3 | 2 | — | — | — | — | — | |
| Consolidated Net Income | -44 | 6 | 28 | -12 | — | — | — | — | — | |
| Net Income From Continuing Operations | -44 | 6 | 28 | -12 | — | — | — | — | — | |
| Net Income | -44 | 6 | 28 | -12 | — | — | — | — | — | |
| EPS (Recurring) | -0.14 | 0.02 | 0.10 | -0.04 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.14 | 0.02 | 0.10 | -0.04 | — | — | — | — | — | |
| EPS (Diluted) | -0.14 | 0.02 | 0.10 | -0.04 | — | — | — | — | — | |
| EBITDA | 29 | 28 | 77 | 16 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 283.50 | 66.15 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.87 | 4.97 | 6.16 | 4.88 | — | — | — | — | — | |
| Gross Margin | 75.83 | 82.52 | 73.08 | 68.34 | — | — | — | — | — | |
| Operating Margin | 2.04 | 11.17 | 25.52 | 4.52 | — | — | — | — | — | |
| Net Margin | -11.20 | 1.72 | 9.79 | -6.03 | — | — | — | — | — | |
| Shares Outstanding | 309 | 306 | 274 | 267 | — | — | — | — | — | |
| Market Capitalization | 1,128 | 1,735 | 1,762 | 972 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director | Sep 25 '26 | Sale | 3.29 | 39,051 | 128,478 | 713,258 | Sep 28 |
| Binder Steven B. | Director | Sep 10 '26 | Sale | 3.81 | 33,558 | 127,856 | 752,309 | Sep 14 |
| Binder Steven B. | Director | Aug 07 '26 | Sale | 4.06 | 39,051 | 158,547 | 785,867 | Aug 10 |
| Thomson David | EVP Genl Counsel & Secretary | Jul 17 '26 | Sale | 4.05 | 24,109 | 97,641 | 797,554 | Jul 17 |
| Binder Steven B. | Director | Jul 17 '26 | Sale | 4.06 | 52,485 | 213,089 | 824,918 | Jul 17 |
| Castagna Michael | Chief Executive Officer | Jul 15 '26 | Option Exercise | 0.00 | 350,260 | 0 | 2,796,979 | Jul 17 |
| Singh Sanjay R | EVP Technical Operations | Jul 15 '26 | Option Exercise | 0.00 | 70,550 | 0 | 525,761 | Jul 17 |
| Thomson David | EVP Genl Counsel & Secretary | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 920,089 | Jul 17 |
| Binder Steven B. | Director | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 901,798 | Jul 17 |
| Tross Stuart A | Chief People & Workpl Officer | Jul 15 '26 | Option Exercise | 0.00 | 93,790 | 0 | 1,123,950 | Jul 17 |
| Binder Steven B. | Director | May 12 '26 | Sale | 3.29 | 16,940 | 55,733 | 808,008 | May 13 |
| Thomson David | EVP Genl Counsel & Secretary | May 12 '26 | Sale | 3.29 | 3,033 | 9,979 | 826,299 | May 13 |
| Castagna Michael | Chief Executive Officer | Mar 10 '26 | Buy | 2.59 | 100,000 | 259,000 | 2,575,911 | Mar 10 |
| Tross Stuart A | Chief People & Workpl Officer | Jan 08 '26 | Sale | 6.33 | 47,006 | 297,548 | 985,007 | Jan 09 |
| Castagna Michael | Chief Executive Officer | Dec 17 '25 | Option Exercise | 4.55 | 115,804 | 526,908 | 2,570,596 | Dec 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.